Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01014286 · ClinicalTrials.gov registry record
Lung Cancer Mutation Consortium Protocol
A clinical trial, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- 1,100
- Enrollment target
NCT01014286: Completed study, sponsored by University of Colorado, Denver.
NCT01014286 is a clinical trial that has completed, run by University of Colorado, Denver. The registered enrollment target is 1,100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01014286 has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- 1,100 participants
- Enrollment target
Study Summary
The primary objective of this protocol is to determine the frequency of oncogenic mutations in 1000 patients with advanced adenocarcinoma of the lung. The linked clinical and mutational analyses will be used to determine the frequency of each mutation, its association with clinical features and outcome, and its association with other mutations. As future therapeutic protocols specific for these mutations are developed, patients may be notified of their eligibility for these studies. Future translational studies may be used to: a) unravel the complex biology of lung cancer; b) identify prognostic markers; c) define predictive markers of response/resistance to new therapies; d) identify new targets. A secondary goal is to establish a consortium of sites that have the capability of conducting multiple mutation testing in a Clinical Laboratory Improvement Amendments (CLIA) certified lab.
Primary Outcome
The primary objective of this protocol is to determine the frequency of oncogenic mutations in patients with advanced adenocarcinoma of the lung.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,100 participants |
| Start Date | 2009-09-16 |
| Est. Completion | 2019-01-12 |
What the finished NCT01014286 record still lists
NCT01014286 is an observational study that tracks outcomes without assigning an intervention. Its 1,100 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT01014286 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01014286 about?
NCT01014286 is a clinical study titled "Lung Cancer Mutation Consortium Protocol". The primary objective of this protocol is to determine the frequency of oncogenic mutations in 1000 patients with advanced adenocarcinoma of the lung. The linked clinical and mutational analyses will be used to determine the frequency of each mutation, its association with clinical features and outc...
What is the current status of trial NCT01014286?
This trial is currently completed. The enrollment target is 1,100 participants. The study started on 2009-09-16. Estimated completion is 2019-01-12.
Who is sponsoring clinical trial NCT01014286?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00710112 · 1,100 participants
Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants
- NCT02688517 · 1,100 participants
Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer
- NCT04743765 · 1,100 participants · NA
HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial
- NCT05638581 · 1,100 participants · Phase 3
Trauma Resuscitation With Low-Titer Group O Whole Blood or Products
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI